[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
IJRR Information::
For Authors::
For Reviewers::
News & Events::
Web Mail::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Hard Copy 2322-3243
Online 2345-4229
Online Submission
Now you can send your articles to IJRR office using the article submission system.



:: Volume 19, Issue 1 (1-2021) ::
Int J Radiat Res 2021, 19(1): 1-12 Back to browse issues page
Chemoradiotherapy alone or in combination with Endostar for patients with advanced non-small cell lung cancer: A systematic review and meta-analysis
Z.C. Tao , J. Qiu , Y.Y. Zhang , L. Qian , J. Gao , Y. Zhou , L. Yang , J. He , J. Yang , R. Wang , Y. Huang , L. Zhou , B. Sun , Y.Y. Cui
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China , money2004@sina.com
Abstract:   (3146 Views)
Previous studies show inconsistent effect estimates for the efficacy of Endostar in patients with advanced non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy. Therefore, this meta-analysis aimed to determine the effectiveness and safety on the basis of data obtained from available randomized controlled trials (RTCs). We find relevant articles reporting the use of Endostar combined with chemoradiotherapy regimens in the treatment of advanced NSCLC. The retrieval period was from June 2008 to June 2018. A total of 11 RTCs that recruited a total of 735 patients were included. Overall, the results indicated that patients who received Endostar plus chemoradiotherapy showed a significantly increased incidence of objective response rate (ORR) (relative risk [RR] = 1.48; 95% confidence interval [CI] = 1.31–1.67; P < 0.00001) and disease control rate (DCR) (RR = 1.17; 95% CI = 1.09–1.25; P < 0.00001) compared with those who received chemoradiotherapy alone. However, no significant difference was noted between groups for 1-year survival rate (RR = 1.06; 95% CI = 0.91–1.23; P = 0.48). Furthermore, combined Endostar with chemoradiotherapy did not yield a high incidence of stable and elevated Karnofsky performance score (RR = 1.06; 95% CI = 0.91–1.23; P = 0.48). Moreover, no significant difference was noted in the incidence of total toxicity between the two groups. The findings of our study indicated that treatment with Endostar plus chemoradiotherapy yielded a high incidence of ORR or DCR, but did not trigger excess adverse events in patients with NSCLC.
Keywords: Endostar, Lung cancer, Chemoradiotherapy, Meta-analysis, Efficacy, Safety.
Full-Text [PDF 2331 kb]   (1052 Downloads)    
Type of Study: Review article | Subject: Medical Physics
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tao Z, Qiu J, Zhang Y, Qian L, Gao J, Zhou Y, et al . Chemoradiotherapy alone or in combination with Endostar for patients with advanced non-small cell lung cancer: A systematic review and meta-analysis. Int J Radiat Res 2021; 19 (1) :1-12
URL: http://ijrr.com/article-1-3443-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 1 (1-2021) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4652